Rallybio Corp
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
RLYB$15.76+0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Condensed Consolidated Statements of Cash Flows
Condensed Consolidated Statements of Cash Flows
| FOR THE SIX MONTHS ENDED JUNE 30, | ||
|---|---|---|
| (in thousands) | 2024 | 2023 |
| Cash Flows Used in Operating Activities: | ||
| Net loss | $(35,265) | $(35,948) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 69 | 77 |
| Net accretion of discounts/premiums on debt securities | (955) | (1,729) |
| Stock-based compensation | 4,003 | 5,737 |
| Loss on investment in joint venture | 1,172 | 780 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses, right-of-use assets and other assets | 2,134 | 1,595 |
| Accounts payable | 242 | (387) |
| Accrued expenses and operating lease liabilities | 1,328 | (2,274) |
| Deferred revenue | 1,397 | — |
| Net cash used in operating activities | (25,875) | (32,149) |
| Cash Flows Provided By (Used In) Investing Activities: | ||
| Purchases of marketable securities | (29,890) | (61,603) |
| Proceeds from maturities of marketable securities | 44,250 | 70,032 |
| Investment in joint venture | (1,500) | (750) |
| Net cash provided by investing activities | 12,860 | 7,679 |
| Cash Flows Provided By (Used In) Financing Activities: | ||
| Proceeds from the issuance of common stock from a securities purchase agreement | 5,405 | — |
| Proceeds from the issuance of common stock under the stock purchase plan | 44 | 209 |
| Payments of offering costs | (257) | (138) |
| Net cash provided by financing activities | 5,192 | 71 |
| Net decrease in cash and cash equivalents | (7,823) | (24,399) |
| Cash and cash equivalents — beginning of period | 24,494 | 56,958 |
| Cash and cash equivalents — end of period | $16,671 | $32,559 |
| Supplemental Disclosures of Noncash Financing Activities: | ||
| Offering costs in accrued expenses | $11 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.